Subnormal	O
Cytokine	B-GP
Profile	O
in	O
the	O
Tear	O
Fluid	O
of	O
Keratoconus	B-DS
Patients	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
SC	O
ASJ	O
AH	O
.	O

Performed	O
the	O
experiments	O
:	O
CS	O
HM	O
XF	O
.	O

Analyzed	O
the	O
data	O
:	O
SC	O
LC	O
.	O

Wrote	O
the	O
paper	O
:	O
SC	O
ASJ	O
.	O

Troubleshooting	O
ELISAs	O
,	O
preparation	O
of	O
figures	O
and	O
tables	O
:	O
SL	O
.	O

Keratoconus	B-DS
,	O
historically	O
viewed	O
as	O
a	O
non	O
-	O
inflammatory	B-DS
disease	I-DS
,	O
is	O
an	O
ectatic	O
corneal	B-DS
disorder	I-DS
associated	O
with	O
progressive	O
thinning	O
of	O
the	O
corneal	O
stroma	O
.	O

Recently	O
,	O
a	O
few	O
inflammatory	O
mediators	O
have	O
been	O
reported	O
to	O
be	O
elevated	O
in	O
the	O
tear	O
fluid	O
of	O
keratoconus	B-DS
patients	O
.	O

Consequently	O
,	O
we	O
investigated	O
a	O
wide	O
range	O
of	O
inflammation	O
regulating	O
cytokines	B-GP
in	O
the	O
tears	O
and	O
sera	O
of	O
keratoconus	B-DS
and	O
control	O
subjects	O
.	O

Interleukin	B-GP
(	O
IL	O
)-	O
1β	O
,	O
IL	B-GP
-	I-GP
4	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
IL	B-GP
-	I-GP
13	I-GP
,	O
IL	B-GP
-	I-GP
17	I-GP
,	O
interferon	B-GP
(	O
IFN	O
)-	O
γ	O
,	O
chemokine	B-GP
C	I-GP
-	I-GP
C	I-GP
motif	I-GP
ligand	I-GP
5	I-GP
(	O
CCL5	B-GP
)	O
and	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
(	O
TNF	O
)-	O
α	O
were	O
tested	O
in	O
tear	O
samples	O
and	O
sera	O
of	O
keratoconus	B-DS
and	O
control	O
individuals	O
by	O
multiplex	O
immuno	O
-	O
bead	O
assays	O
.	O

Selected	O
cytokines	B-GP
were	O
further	O
tested	O
by	O
standard	O
ELISA	O
on	O
pooled	O
tear	O
samples	O
.	O

All	O
cytokines	B-GP
in	O
the	O
sera	O
were	O
generally	O
low	O
,	O
with	O
no	O
significant	O
changes	O
between	O
keratoconus	B-DS
and	O
control	O
subjects	O
.	O

However	O
,	O
in	O
tear	O
fluids	O
,	O
clear	O
differences	O
were	O
detected	O
between	O
the	O
two	O
groups	O
.	O

These	O
differences	O
include	O
increased	O
IL	B-GP
-	I-GP
6	I-GP
,	O
and	O
decreased	O
IL	B-GP
-	I-GP
12	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
IL	B-GP
-	I-GP
4	I-GP
,	O
IL	B-GP
-	I-GP
13	I-GP
and	O
CCL5	B-GP
in	O
keratoconus	B-DS
compared	O
to	O
control	O
tear	O
fluids	O
.	O

The	O
decreases	O
in	O
IL	B-GP
-	I-GP
12	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
CCL5	B-GP
were	O
statistically	O
significant	O
,	O
while	O
the	O
IL	B-GP
-	I-GP
13	I-GP
decrease	O
was	O
statistically	O
significant	O
in	O
the	O
severe	O
keratoconus	B-DS
group	O
only	O
.	O

IL	B-GP
-	I-GP
17	I-GP
could	O
not	O
be	O
detected	O
by	O
multiplex	O
immuno	O
-	O
bead	O
assay	O
,	O
but	O
showed	O
an	O
increase	O
in	O
keratoconus	B-DS
by	O
conventional	O
ELISA	O
on	O
a	O
limited	O
number	O
of	O
pooled	O
tear	O
samples	O
.	O

Our	O
findings	O
confirm	O
increased	O
IL	B-GP
-	I-GP
6	I-GP
,	O
but	O
dispute	O
earlier	O
reports	O
of	O
increased	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
and	O
suggest	O
a	O
cytokine	B-GP
imbalance	O
in	O
keratoconus	B-DS
disrupting	O
corneal	O
homeostasis	O
.	O

Moreover	O
,	O
an	O
increase	O
in	O
IL	B-GP
-	I-GP
17	I-GP
suggests	O
tissue	O
degenerative	O
processes	O
at	O
work	O
,	O
contributing	O
to	O
the	O
thinning	O
and	O
weakening	O
of	O
the	O
corneal	O
connective	O
tissue	O
in	O
keratoconus	B-DS
.	O

Introduction	O

Keratoconus	B-DS
is	O
an	O
ectatic	O
corneal	B-DS
disease	I-DS
associated	O
with	O
progressive	O
thinning	O
of	O
the	O
corneal	O
stroma	O
,	O
and	O
a	O
protruding	O
,	O
cone	O
-	O
shaped	O
cornea	O
that	O
produces	O
astigmatism	B-DS
and	O
myopia	B-DS
.	O

Keratoconus	B-DS
is	O
a	O
leading	O
cause	O
of	O
corneal	O
transplantation	O
,	O
affecting	O
1	O
in	O
2000	O
individuals	O
with	O
a	O
mean	O
age	O
of	O
onset	O
at	O
15	O
.	O
4	O
years	O
[	O
1	O
],	O
[	O
2	O
],	O
[	O
3	O
],	O
[	O
4	O
].	O

The	O
disorder	O
typically	O
progresses	O
until	O
the	O
third	O
to	O
fourth	O
decade	O
of	O
life	O
[	O
3	O
],	O
and	O
the	O
factors	O
that	O
determine	O
the	O
progression	O
or	O
stabilization	O
of	O
the	O
disease	O
are	O
not	O
well	O
characterized	O
or	O
understood	O
.	O

Although	O
the	O
etiology	O
of	O
keratoconus	B-DS
is	O
poorly	O
understood	O
,	O
it	O
is	O
traditionally	O
viewed	O
as	O
a	O
non	B-DS
-	I-DS
inflammatory	I-DS
corneal	I-DS
thinning	I-DS
disease	I-DS
[	O
1	O
].	O

Accordingly	O
,	O
cellular	O
infiltration	O
and	O
vascularization	O
are	O
not	O
clinically	O
apparent	O
in	O
keratoconus	B-DS
.	O

However	O
,	O
keratoconus	B-DS
has	O
been	O
linked	O
to	O
atopy	O
since	O
the	O
1950s	O
[	O
5	O
],	O
with	O
further	O
support	O
coming	O
from	O
later	O
studies	O
that	O
reported	O
elevated	O
levels	O
of	O
immunoglobulin	B-GP
(	B-GP
Ig	I-GP
)	I-GP
E	I-GP
in	O
the	O
sera	O
of	O
keratoconus	B-DS
patients	O
[	O
6	O
],	O
[	O
7	O
].	O

Recent	O
studies	O
have	O
suggested	O
pro	O
-	O
inflammatory	O
factors	O
as	O
key	O
to	O
keratoconus	B-DS
pathogenesis	O
based	O
on	O
their	O
findings	O
of	O
elevated	O
interleukin	B-GP
(	B-GP
IL	I-GP
)-	I-GP
6	I-GP
,	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
(	O
TNF	O
)-	O
α	O
and	O
matrix	B-GP
metalloproteinase	I-GP
(	B-GP
MMP	I-GP
)-	I-GP
9	I-GP
in	O
the	O
tear	O
fluid	O
of	O
keratoconus	B-DS
patients	O
[	O
8	O
],	O
[	O
9	O
].	O

Moreover	O
,	O
increased	O
binding	O
of	O
IL	B-GP
-	I-GP
1	I-GP
by	O
keratoconus	B-DS
corneal	O
fibroblasts	O
has	O
led	O
another	O
group	O
to	O
suggest	O
a	O
role	O
for	O
inflammation	O
in	O
the	O
onset	O
or	O
progression	O
of	O
keratoconus	B-DS
as	O
well	O
[	O
10	O
].	O

Despite	O
these	O
initial	O
findings	O
of	O
specific	O
changes	O
in	O
inflammatory	O
cytokines	B-GP
,	O
there	O
are	O
no	O
studies	O
that	O
have	O
examined	O
a	O
range	O
of	O
cytokines	B-GP
to	O
determine	O
whether	O
keratoconus	B-DS
is	O
associated	O
with	O
an	O
imbalance	O
in	O
the	O
repertoire	O
of	O
cytokines	B-GP
that	O
regulate	O
inflammatory	O
and	O
immune	O
responses	O
driven	O
by	O
subsets	O
of	O
T	O
-	O
helper	O
cells	O
,	O
TH1	O
,	O
TH2	O
,	O
and	O
TH17	O
in	O
the	O
corneal	O
environment	O
.	O

To	O
begin	O
addressing	O
this	O
question	O
,	O
we	O
quantified	O
TH1	O
cytokines	B-GP
(	O
IL	B-GP
-	I-GP
12	I-GP
,	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
TNF	B-GP
-	I-GP
α	I-GP
),	O
TH2	O
cytokines	B-GP
(	O
IL	B-GP
-	I-GP
4	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
and	O
IL	B-GP
-	I-GP
13	I-GP
),	O
the	O
TH17	O
representative	O
cytokine	B-GP
IL	B-GP
-	I-GP
17	I-GP
,	O
and	O
other	O
inflammatory	O
cytokines	B-GP
/	O
chemokines	B-GP
(	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
and	O
RANTES	B-GP
or	O
CCL5	B-GP
)	O
in	O
tear	O
fluids	O
and	O
serum	O
samples	O
of	O
keratoconus	B-DS
patients	O
and	O
control	O
subjects	O
.	O

Although	O
this	O
initial	O
study	O
is	O
based	O
on	O
a	O
relatively	O
small	O
sample	O
size	O
,	O
decreases	O
in	O
specific	O
cytokines	B-GP
suggest	O
down	O
regulations	O
of	O
both	O
pro	O
-	O
inflammatory	O
and	O
immunoprotective	O
responses	O
to	O
play	O
a	O
role	O
in	O
this	O
disease	O
.	O

Results	O

Demographics	O

A	O
set	O
of	O
18	O
keratoconus	B-DS
(	O
KC	B-DS
)	O
and	O
11	O
controls	O
were	O
used	O
for	O
the	O
multiplex	O
cytokine	B-GP
analyses	O
on	O
tear	O
fluids	O
and	O
sera	O
(	O
Table	O
1	O
).	O

Two	O
(	O
11	O
%)	O
of	O
the	O
KC	B-DS
patients	O
were	O
graded	O
as	O
mild	O
(	O
steepest	O
K	O
<	O
45D	O
),	O
6	O
(	O
33	O
%)	O
as	O
moderate	O
(	O
45D	O
≤	O
steepest	O
K	O
≤	O
52D	O
),	O
and	O
10	O
(	O
56	O
%)	O
as	O
severe	O
(	O
steepest	O
K	O
>	O
52D	O
).	O

Using	O
the	O
Mann	O
-	O
Whitney	O
test	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
02	O
),	O
10	O
year	O
difference	O
in	O
the	O
mean	O
age	O
between	O
the	O
controls	O
and	O
the	O
keratoconus	B-DS
subjects	O
,	O
who	O
were	O
on	O
average	O
33	O
and	O
43	O
years	O
old	O
,	O
respectively	O
.	O

Nine	O
of	O
the	O
KC	B-DS
and	O
four	O
of	O
the	O
control	O
subjects	O
wore	O
contact	O
lenses	O
.	O

Due	O
to	O
their	O
disease	O
status	O
,	O
keratoconus	B-DS
patients	O
normally	O
wear	O
hard	O
contact	O
lenses	O
,	O
while	O
unaffected	O
subjects	O
wear	O
soft	O
contact	O
lenses	O
.	O

Although	O
matching	O
by	O
contact	O
lens	O
use	O
would	O
not	O
per	O
se	O
remove	O
this	O
difference	O
,	O
to	O
determine	O
if	O
contact	O
lens	O
use	O
had	O
an	O
effect	O
,	O
irrespective	O
of	O
disease	O
status	O
,	O
we	O
fit	O
a	O
multivariate	O
linear	O
model	O
to	O
determine	O
the	O
effects	O
of	O
contact	O
lens	O
wear	O
on	O
tear	O
fluid	O
cytokine	B-GP
levels	O
after	O
adjusting	O
for	O
the	O
age	O
of	O
the	O
subjects	O
.	O

Levels	O
of	O
all	O
cytokines	B-GP
tested	O
were	O
higher	O
in	O
the	O
13	O
contact	O
lens	O
users	O
when	O
compared	O
to	O
non	O
-	O
contact	O
lens	O
users	O
,	O
and	O
while	O
the	O
differences	O
were	O
moderate	O
for	O
some	O
of	O
the	O
cytokines	B-GP
,	O
they	O
were	O
not	O
statistically	O
significant	O
except	O
for	O
IL	B-GP
-	I-GP
4	I-GP
(	O
Table	O
S1	O
).	O

The	O
average	O
time	O
since	O
diagnosis	O
of	O
keratoconus	B-DS
was	O
16	O
±	O
14	O
(	O
mean	O
±	O
SD	O
)	O
years	O
(	O
Table	O
1	O
).	O

Three	O
of	O
the	O
18	O
keratoconus	B-DS
patients	O
had	O
a	O
medical	O
history	O
including	O
atopy	O
.	O

Tear	O
fluid	O
samples	O
were	O
collected	O
between	O
9	O
am	O
and	O
4	O
pm	O
,	O
with	O
no	O
statistically	O
significant	O
differences	O
in	O
collection	O
times	O
between	O
control	O
and	O
keratoconus	B-DS
subjects	O
.	O

We	O
also	O
noted	O
that	O
the	O
keratoconus	B-DS
group	O
was	O
ethnically	O
more	O
diverse	O
than	O
the	O
control	O
group	O
.	O

Our	O
recent	O
efforts	O
are	O
geared	O
towards	O
collecting	O
tear	O
samples	O
from	O
appropriately	O
matched	O
control	O
subjects	O
,	O
and	O
when	O
applicable	O
to	O
collect	O
tear	O
fluids	O
from	O
the	O
unaffected	O
eye	O
of	O
keratoconus	B-DS
patients	O
as	O
well	O
.	O

Keratoconus	B-DS
and	O
control	O
samples	O
for	O
immuno	O
-	O
bead	O
multiplex	O
ELISA	O
.	O

Sample	O

Age	O

Gender	O

Contact	O
lens	O

Diagnosis	O

Number	O

Group	O

Severity	O

(	O
years	O
)	O

(	O
M	O
/	O
F	O
)	O

Race	O

use	O
(	O
years	O
)	O

(	O
years	O
)	O

1	O

KC	B-DS

Severe	O

42	O

M	O

Black	O

None	O

?	O

2	O

KC	B-DS

Severe	O

44	O

F	O

Native	O
American	O

30	O
.	O
0	O

32	O

3	O

KC	B-DS

Mild	O

52	O

F	O

White	O

Intolerant	O

?	O

4	O

KC	B-DS

Severe	O

34	O

F	O

White	O

None	O

9	O

5	O

KC	B-DS

-	O

76	O

F	O

Black	O

42	O
.	O
0	O

42	O

6	O

KC	B-DS

Mild	O

38	O

M	O

Asian	O

Yes	O

10	O

7	O

KC	B-DS

-	O

45	O

M	O

White	O

None	O

7	O

8	O

KC	B-DS

Severe	O

30	O

M	O

Black	O

Yes	O

?	O

9	O

KC	B-DS

Severe	O

31	O

M	O

Native	O
American	O

None	O

3	O

10	O

KC	B-DS

Severe	O

27	O

M	O

Asian	O

None	O

6	O

11A	O

KC	B-DS

Severe	O

27	O

M	O

Native	O
American	O

None	O

10	O

12	O

KC	B-DS

Severe	O

35	O

M	O

White	O

None	O

9	O

13	O

KC	B-DS

Mild	O

32	O

F	O

Native	O
American	O

5	O
.	O
0	O

8	O

14A	O

KC	B-DS

Mild	O

61	O

F	O

White	O

20	O
.	O
0	O

25	O

15	O

KC	B-DS

-	O

61	O

M	O

White	O

None	O

48	O

16A	O

KC	B-DS

Mild	O

40	O

M	O

White	O

24	O
.	O
0	O

7	O

17	O

KC	B-DS

Mild	O

56	O

F	O

Black	O

Yes	O

22	O

18	O

KC	B-DS

Mild	O

53	O

M	O

White	O

27	O
.	O
0	O

8	O

Mean	O

44	O

24	O
.	O
7	O

16	O

SD	O

14	O

12	O
.	O
2	O

14	O

1	O

Control	O

N	O
/	O
A	O

22	O

F	O

White	O

10	O
.	O
0	O

N	O
/	O
A	O

2	O

Control	O

N	O
/	O
A	O

50	O

F	O

White	O

None	O

N	O
/	O
A	O

3	O

Control	O

N	O
/	O
A	O

51	O

M	O

White	O

None	O

N	O
/	O
A	O

4	O

Control	O

N	O
/	O
A	O

30	O

M	O

Native	O
American	O

None	O

N	O
/	O
A	O

5	O

Control	O

N	O
/	O
A	O

40	O

M	O

Asian	O

None	O

N	O
/	O
A	O

6	O

Control	O

N	O
/	O
A	O

31	O

F	O

White	O

10	O
.	O
0	O

N	O
/	O
A	O

7	O

Control	O

N	O
/	O
A	O

24	O

M	O

White	O

9	O
.	O
0	O

N	O
/	O
A	O

8	O

Control	O

N	O
/	O
A	O

30	O

M	O

White	O

None	O

N	O
/	O
A	O

9	O

Control	O

N	O
/	O
A	O

31	O

F	O

White	O

None	O

N	O
/	O
A	O

10	O

Control	O

N	O
/	O
A	O

30	O

F	O

White	O

None	O

N	O
/	O
A	O

11	O

Control	O

N	O
/	O
A	O

24	O

F	O

White	O

10	O
.	O
0	O

N	O
/	O
A	O

Mean	O

33	O

9	O
.	O
8	O

SD	O

10	O

0	O
.	O
5	O

A	O
;	O
atopy	O
,	O
KC	B-DS
:	O
keratoconus	B-DS
,	O
M	O
;	O
male	O
,	O
F	O
:	O
female	O
,	O
SD	O
:	O
1	O
standard	O
deviation	O
,	O
N	O
/	O
A	O
:	O
not	O
applicable	O
,	O

-	O
Unable	O
to	O
obtain	O
a	O
keratometry	O
measurement	O
for	O
severity	O
due	O
to	O
irregular	O
curvature	O
of	O
patient	O
'	O
s	O
cornea	O
.	O

A	O
second	O
set	O
of	O
samples	O
comprising	O
29	O
KC	B-DS
and	O
38	O
control	O
samples	O
were	O
collected	O
for	O
performing	O
individual	O
ELISA	O
assays	O
for	O
validation	O
purposes	O
(	O
Table	O
S2	O
).	O

In	O
this	O
set	O
,	O
the	O
control	O
subjects	O
were	O
matched	O
more	O
closely	O
to	O
the	O
KC	B-DS
group	O
for	O
age	O
and	O
ethnicity	O
.	O

The	O
mean	O
±	O
SD	O
ages	O
were	O
38	O
±	O
10	O
and	O
40	O
±	O
12	O
years	O
,	O
for	O
KC	B-DS
and	O
control	O
subjects	O
,	O
respectively	O
.	O

Some	O
of	O
the	O
KC	B-DS
subjects	O
wore	O
contact	O
lenses	O
,	O
while	O
the	O
control	O
subjects	O
for	O
this	O
group	O
were	O
not	O
contact	O
lens	O
users	O
(	O
Table	O
S2	O
).	O

Of	O
the	O
keratoconus	B-DS
and	O
control	O
cases	O
(	O
Table	O
S2	O
),	O
atopy	O
was	O
reported	O
for	O
six	O
and	O
four	O
of	O
the	O
individuals	O
,	O
respectively	O
.	O

Multiplex	O
cytokine	B-GP
analysis	O
of	O
keratoconus	B-DS
and	O
control	O
subjects	O

To	O
investigate	O
the	O
relationship	O
between	O
disease	O
status	O
and	O
cytokine	B-GP
levels	O
,	O
we	O
performed	O
a	O
linear	O
multivariate	O
correlation	O
study	O
of	O
natural	O
log	O
transformed	O
cytokine	B-GP
levels	O
and	O
disease	O
,	O
after	O
correcting	O
for	O
age	O
and	O
contact	O
lens	O
use	O
,	O
as	O
covariates	O
.	O

The	O
results	O
were	O
reported	O
as	O
significant	O
in	O
Table	O
2	O
,	O
only	O
if	O
disease	O
was	O
a	O
significant	O
independent	O
predictor	O
of	O
cytokine	B-GP
levels	O
.	O

All	O
cytokines	B-GP
tested	O
by	O
multiplex	O
immuno	O
-	O
bead	O
assay	O
,	O
except	O
IL	B-GP
-	I-GP
17	I-GP
,	O
were	O
detectable	O
in	O
tear	O
samples	O
.	O
Table	O
2	O
shows	O
median	O
,	O
25th	O
and	O
75th	O
percentile	O
values	O
of	O
tear	O
fluid	O
cytokines	B-GP
of	O
all	O
keratoconus	B-DS
and	O
control	O
subjects	O
.	O

Overall	O
,	O
we	O
found	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
were	O
3	O
fold	O
elevated	O
(	O
based	O
on	O
mean	O
values	O
)	O
in	O
keratoconus	B-DS
samples	O
compared	O
to	O
control	O
subjects	O
(	O
Table	O
2	O
and	O
Figure	O
1	O
),	O
confirming	O
a	O
previous	O
report	O
of	O
increased	O
IL	B-GP
-	I-GP
6	I-GP
in	O
keratoconus	B-DS
[	O
8	O
].	O

The	O
increase	O
in	O
IL	B-GP
-	I-GP
6	I-GP
did	O
not	O
reach	O
statistical	O
significance	O
due	O
to	O
the	O
variation	O
in	O
levels	O
between	O
subjects	O
.	O

IL	B-GP
-	I-GP
1β	I-GP
was	O
essentially	O
unchanged	O
,	O
while	O
the	O
remaining	O
cytokines	B-GP
showed	O
decreased	O
levels	O
in	O
our	O
keratoconus	B-DS
samples	O
.	O

After	O
subtracting	O
the	O
effects	O
of	O
age	O
and	O
contact	O
lens	O
use	O
,	O
the	O
decreases	O
in	O
TH1	O
related	O
cytokines	B-GP
IL	B-GP
-	I-GP
12	I-GP
(	O
p	O
=	O
0	O
.	O
03	O
),	O
TNF	B-GP
-	I-GP
α	I-GP
(	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
CCL5	B-GP
(	O
p	O
=	O
0	O
.	O
05	O
)	O
were	O
statistically	O
significant	O
.	O

The	O
decrease	O
in	O
TNF	B-GP
-	I-GP
α	I-GP
seen	O
here	O
,	O
contradicts	O
an	O
earlier	O
observation	O
of	O
increased	O
TNF	B-GP
-	I-GP
α	I-GP
in	O
keratoconus	B-DS
.	O

Statistical	O
differences	O
in	O
cytokine	B-GP
levels	O
were	O
also	O
analyzed	O
after	O
stratifying	O
the	O
keratoconus	B-DS
group	O
into	O
mild	O
/	O
moderate	O
(	O
steepest	O
K	O
≤	O
52D	O
)	O
and	O
severe	O
(	O
steepest	O
K	O
>	O
52	O
D	O
)	O
groups	O
.	O

No	O
significant	O
differences	O
were	O
evident	O
when	O
the	O
mild	O
to	O
moderate	O
disease	O
was	O
compared	O
to	O
the	O
controls	O
(	O
analysis	O
not	O
shown	O
).	O

The	O
comparison	O
of	O
the	O
data	O
from	O
severe	O
KC	B-DS
to	O
that	O
of	O
controls	O
is	O
shown	O
in	O
Table	O
3	O
.	O

Despite	O
the	O
resulting	O
decrease	O
in	O
sample	O
size	O
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
CCL5	B-GP
showed	O
even	O
stronger	O
effects	O
in	O
severe	O
keratoconus	B-DS
.	O

The	O
IFN	B-GP
-	I-GP
γ	I-GP
decrease	O
in	O
keratoconus	B-DS
compared	O
to	O
controls	O
was	O
significant	O
by	O
Mann	O
-	O
Whitney	O
testing	O
(	O
p	O
=	O
0	O
.	O
02	O
,	O
analysis	O
not	O
shown	O
),	O
but	O
not	O
by	O
multivariate	O
analysis	O
,	O
where	O
the	O
large	O
variance	O
of	O
the	O
measurements	O
appeared	O
to	O
diminish	O
its	O
significance	O
(	O
Table	O
3	O
).	O

Of	O
the	O
TH2	O
-	O
related	O
cytokines	B-GP
,	O
the	O
decrease	O
in	O
IL	B-GP
-	I-GP
13	I-GP
was	O
statistically	O
significant	O
in	O
severe	O
keratoconus	B-DS
versus	O
control	O
subjects	O
.	O

The	O
multiplex	O
immuno	O
-	O
bead	O
assay	O
could	O
not	O
detect	O
IL	B-GP
-	I-GP
17	I-GP
in	O
control	O
or	O
keratoconus	B-DS
tear	O
samples	O
.	O

Atopy	O
was	O
not	O
considered	O
as	O
a	O
testable	O
variable	O
since	O
it	O
was	O
detected	O
in	O
similar	O
numbers	O
in	O
keratoconus	B-DS
and	O
control	O
individuals	O
.	O

We	O
found	O
no	O
correlation	O
(	O
Methods	O
)	O
between	O
the	O
time	O
of	O
tear	O
fluid	O
collection	O
and	O
cytokine	B-GP
levels	O
(	O
not	O
shown	O
).	O

Cytokine	B-GP
measurements	O
in	O
tear	O
fluids	O
by	O
a	O
multiplex	O
immuno	O
-	O
bead	O
assay	O
.	O

Each	O
cytokine	B-GP
was	O
measured	O
in	O
individual	O
subjects	O
.	O

The	O
horizontal	O
bar	O
indicates	O
the	O
mean	O
value	O
for	O
each	O
group	O
.	O

After	O
correcting	O
for	O
age	O
and	O
contact	O
lens	O
use	O
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
and	O
RANTES	B-GP
/	O
CCL5	B-GP
were	O
significantly	O
lower	O
in	O
KC	B-DS
than	O
in	O
controls	O
.	O

Statistical	O
analyses	O
of	O
the	O
data	O
are	O
shown	O
in	O
Tables	O
2	O
and	O
3	O
.	O

Tear	O
-	O
fluid	O
cytokine	B-GP
concentrations	O
in	O
keratoconus	B-DS
and	O
control	O
subjects	O
.	O

Control	O
(	O
C	O
)	O

Keratoconus	B-DS
(	O
KC	B-DS
)	O

Fold	O

Median	O
,	O
quartilesa	O

Mean	O
±	O
SD	O

Median	O
,	O
quartilesa	O

Mean	O
±	O
SD	O

change	O

p	O
–	O

Cytokine	B-GP

pg	O
/	O
ml	O

pg	O
/	O
ml	O

pg	O
/	O
ml	O

pg	O
/	O
ml	O

KC	B-DS
/	O
Cb	O

valuec	O

IL	B-GP
-	I-GP
1β	I-GP

10	O
[	O
3	O
.	O
2	O
,	O
19	O
.	O
4	O
]	O

9	O
.	O
6	O
±	O
7	O
.	O
9	O

6	O
.	O
9	O
[	O
3	O
.	O
6	O
,	O
9	O
.	O
6	O
]	O

8	O
.	O
3	O
±	O
6	O
.	O
7	O

0	O
.	O
88	O

0	O
.	O
87	O

IL	B-GP
-	I-GP
4	I-GP

111	O
.	O
2	O
[	O
52	O
.	O
6	O
,	O
175	O
.	O
1	O
]	O

116	O
.	O
1	O
±	O
81	O
.	O
9	O

38	O
.	O
7	O
[	O
12	O
.	O
8	O
,	O
122	O
.	O
7	O
]	O

69	O
.	O
6	O
±	O
70	O
.	O
7	O

0	O
.	O
6	O

0	O
.	O
43	O

IL	B-GP
-	I-GP
6	I-GP

66	O
.	O
8	O
[	O
27	O
.	O
4	O
,	O
140	O
.	O
4	O
]	O

89	O
.	O
5	O
±	O
83	O
.	O
5	O

72	O
.	O
2	O
[	O
48	O
.	O
9	O
,	O
241	O
]	O

282	O
.	O
7	O
±	O
467	O
.	O
7	O

3	O
.	O
2	O

0	O
.	O
17	O

IL	B-GP
-	I-GP
10	I-GP

10	O
.	O
6	O
[	O
0	O
.	O
7	O
,	O
19	O
.	O
1	O
]	O

16	O
.	O
5	O
±	O
23	O
.	O
5	O

4	O
[	O
0	O
.	O
9	O
,	O
12	O
.	O
1	O
]	O

6	O
.	O
9	O
±	O
7	O
.	O
3	O

0	O
.	O
4	O

0	O
.	O
4	O

IL	B-GP
-	I-GP
12	I-GP

48	O
.	O
6	O
[	O
10	O
.	O
6	O
,	O
142	O
.	O
8	O
]	O

89	O
.	O
8	O
±	O
115	O
.	O
8	O

8	O
.	O
4	O
[	O
1	O
.	O
6	O
,	O
37	O
.	O
1	O
]	O

21	O
.	O
8	O
±	O
26	O
.	O
6	O

0	O
.	O
24	O

0	O
.	O
03	O

IL	B-GP
-	I-GP
13	I-GP

14	O
.	O
7	O
[	O
9	O
.	O
1	O
,	O
46	O
]	O

32	O
.	O
3	O
±	O
33	O
.	O
5	O

7	O
.	O
8	O
[	O
5	O
.	O
7	O
,	O
12	O
.	O
1	O
]	O

11	O
.	O
2	O
±	O
5	O
.	O
9	O

0	O
.	O
35	O

0	O
.	O
11	O

IFN	B-GP
-	I-GP
γ	I-GP

1969	O
[	O
643	O
,	O
4859	O
]	O

2783	O
±	O
2778	O
.	O
7	O

76	O
[	O
19	O
.	O
3	O
,	O
401	O
.	O
6	O
]	O

557	O
.	O
1	O
±	O
1004	O
.	O
3	O

0	O
.	O
2	O

0	O
.	O
2	O

CCL5	B-GP

109	O
.	O
4	O
[	O
57	O
,	O
222	O
]	O

111	O
.	O
3	O
±	O
86	O
.	O
3	O

1	O
.	O
2	O
[	O
1	O
.	O
2	O
,	O
131	O
.	O
7	O
]	O

59	O
.	O
4	O
±	O
68	O
.	O
9	O

0	O
.	O
53	O

0	O
.	O
05	O

TNF	B-GP
-	I-GP
α	I-GP

150	O
[	O
80	O
.	O
5	O
,	O
349	O
.	O
5	O
]	O

252	O
.	O
6	O
±	O
275	O
.	O
3	O

54	O
.	O
6	O
[	O
34	O
.	O
4	O
,	O
122	O
.	O
3	O
]	O

77	O
.	O
1	O
±	O
669	O

0	O
.	O
3	O

0	O
.	O
04	O

25th	O
and	O
75th	O
percentile	O
.	O

fold	O
change	O
in	O
mean	O
values	O
.	O

p	O
value	O
based	O
on	O
a	O
multivariate	O
linear	O
model	O
after	O
correcting	O
for	O
age	O
and	O
contact	O
lens	O
use	O
covariates	O
.	O

Tear	O
-	O
fluid	O
cytokine	B-GP
concentrations	O
in	O
severe	O
(	O
K	O
>	O
52D	O
)	O
keratoconus	B-DS
and	O
control	O
subjects	O
.	O

Control	O
(	O
C	O
)	O

Keratoconus	B-DS
(	O
KC	B-DS
)	O

Fold	O
change	O

Cytokine	B-GP

Mean	O
±	O
SD	O
,	O
pg	O
/	O
ml	O

Mean	O
±	O
SD	O
,	O
pg	O
/	O
ml	O

KC	B-DS
/	O
C	O

p	O
a	O
-	O
value	O

IL	B-GP
-	I-GP
1β	I-GP

12	O
.	O
19	O
±	O
11	O
.	O
56	O

7	O
.	O
46	O
±	O
5	O
.	O
58	O

0	O
.	O
61	O

0	O
.	O
83	O

IL	B-GP
-	I-GP
4	I-GP

116	O
±	O
81	O
.	O
8	O

33	O
.	O
48	O
±	O
49	O
.	O
74	O

0	O
.	O
3	O

0	O
.	O
31	O

IL	B-GP
-	I-GP
6	I-GP

89	O
.	O
64	O
±	O
83	O
.	O
36	O

254	O
±	O
312	O
.	O
41	O

2	O
.	O
83	O

0	O
.	O
27	O

IL	B-GP
-	I-GP
10	I-GP

16	O
.	O
46	O
±	O
23	O
.	O
5	O

7	O
.	O
05	O
±	O
9	O

0	O
.	O
41	O

0	O
.	O
17	O

IL	B-GP
-	I-GP
12	I-GP

90	O
.	O
1	O
±	O
115	O
.	O
57	O

12	O
.	O
57	O
±	O
15	O
.	O
25	O

0	O
.	O
14	O

0	O
.	O
007	O

IL	B-GP
-	I-GP
13	I-GP

32	O
.	O
34	O
±	O
35	O
.	O
1	O

8	O
.	O
79	O
±	O
6	O

0	O
.	O
27	O

0	O
.	O
04	O

IFN	B-GP
-	I-GP
γ	I-GP

2780	O
.	O
6	O
±	O
2781	O
.	O
3	O

543	O
.	O
83	O
±	O
946	O
.	O
28	O

0	O
.	O
2	O

0	O
.	O
133	O

CCL5	B-GP

149	O
±	O
149	O
.	O
4	O

25	O
.	O
8	O
±	O
48	O
.	O
1	O

0	O
.	O
18	O

0	O
.	O
013	O

TNF	B-GP
-	I-GP
α	I-GP

253	O
±	O
275	O

55	O
.	O
06	O
±	O
67	O
.	O
72	O

0	O
.	O
22	O

0	O
.	O
04	O

p	O
value	O
based	O
on	O
a	O
multivariate	O
linear	O
model	O
after	O
correcting	O
for	O
age	O
and	O
contact	O
lens	O
use	O
covariates	O
.	O

In	O
the	O
sera	O
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
keratoconus	B-DS
patients	O
and	O
control	O
subjects	O
for	O
the	O
cytokines	B-GP
tested	O
(	O
Table	O
4	O
).	O

IL	B-GP
-	I-GP
10	I-GP
,	O
IL	B-GP
-	I-GP
12	I-GP
and	O
IL	B-GP
-	I-GP
13	I-GP
could	O
not	O
be	O
detected	O
in	O
any	O
of	O
the	O
sera	O
tested	O
,	O
while	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
IL	B-GP
-	I-GP
4	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
and	O
TNF	B-GP
-	I-GP
α	I-GP
were	O
present	O
at	O
very	O
low	O
levels	O
,	O
and	O
CCL5	B-GP
was	O
clearly	O
detected	O
.	O

Thus	O
,	O
the	O
cytokine	B-GP
changes	O
detected	O
in	O
the	O
tear	O
film	O
are	O
likely	O
a	O
reflection	O
of	O
localized	O
events	O
in	O
the	O
eye	O
and	O
not	O
systemic	O
changes	O
.	O

Serum	O
cytokine	B-GP
concentrations	O
in	O
keratoconus	B-DS
and	O
control	O
subjects	O
.	O

Control	O
(	O
C	O
)	O

Keratoconus	B-DS
(	O
KC	B-DS
)	O

Fold	O
change	O

Cytokine	B-GP

Mean	O
±	O
SD	O
,	O
pg	O
/	O
ml	O

Mean	O
±	O
SD	O
,	O
pg	O
/	O
ml	O

KC	B-DS
/	O
Ca	O

p	O
b	O
-	O
value	O

IL	B-GP
-	I-GP
1β	I-GP

0	O
.	O
18	O
±	O
0	O
.	O
15	O

0	O
.	O
14	O
±	O
0	O
.	O
11	O

0	O
.	O
8	O

0	O
.	O
71	O

IL	B-GP
-	I-GP
4	I-GP

0	O
.	O
09	O
±	O
0	O
.	O
06	O

0	O
.	O
11	O
±	O
0	O
.	O
08	O

1	O
.	O
2	O

0	O
.	O
61	O

IL	B-GP
-	I-GP
6	I-GP

1	O
.	O
77	O
±	O
3	O
.	O
66	O

1	O
.	O
39	O
±	O
2	O
.	O
37	O

0	O
.	O
8	O

0	O
.	O
31	O

IL	B-GP
-	I-GP
10	I-GP

ND	O

ND	O

N	O
/	O
A	O

-	O

IL	B-GP
-	I-GP
12	I-GP

ND	O

ND	O

N	O
/	O
A	O

-	O

IL	B-GP
-	I-GP
13	I-GP

ND	O

ND	O

N	O
/	O
A	O

-	O

IFN	B-GP
-	I-GP
γ	I-GP

27	O
.	O
49	O
±	O
9	O
.	O
73	O

25	O
.	O
84	O
±	O
25	O
.	O
38	O

0	O
.	O
9	O

0	O
.	O
4	O

CCL5	B-GP

100	O
.	O
70	O
±	O
55	O
.	O
61	O

93	O
.	O
19	O
±	O
58	O
.	O
0	O

0	O
.	O
9	O

0	O
.	O
73	O

TNF	B-GP
-	I-GP
α	I-GP

1	O
.	O
46	O
±	O
1	O
.	O
71	O

1	O
.	O
57	O
±	O
1	O
.	O
42	O

1	O
.	O
1	O

1	O
.	O
0	O

Fold	O
change	O
in	O
mean	O
cytokine	B-GP
level	O
.	O

p	O
value	O
based	O
on	O
Mann	O
-	O
Whitney	O
test	O
.	O

ND	O
:	O
Not	O
detectable	O
.	O

All	O
readings	O
were	O
below	O
detection	O
levels	O
.	O

N	O
/	O
A	O
:	O
not	O
applicable	O
.	O

Measurements	O
of	O
selected	O
cytokines	B-GP
in	O
tear	O
fluid	O
by	O
standard	O
ELISA	O

The	O
multiplex	O
data	O
implicate	O
reductions	O
in	O
TH1	O
(	O
IL	B-GP
-	I-GP
12	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
,	O
IFN	B-GP
-	I-GP
γ	I-GP
),	O
and	O
possibly	O
TH2	O
cytokines	B-GP
(	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
13	I-GP
)	O
in	O
keratoconus	B-DS
.	O

To	O
further	O
explore	O
these	O
possibilities	O
,	O
we	O
performed	O
standard	O
individual	O
ELISAs	O
for	O
selected	O
cytokines	B-GP
.	O

In	O
general	O
,	O
the	O
conventional	O
,	O
standard	O
ELISA	O
(	O
high	O
sensitivity	O
)	O
is	O
less	O
sensitive	O
than	O
multiplex	O
immuno	O
-	O
bead	O
assays	O
.	O

Therefore	O
,	O
it	O
was	O
necessary	O
to	O
pool	O
the	O
tear	O
samples	O
from	O
different	O
KC	B-DS
and	O
control	O
subjects	O
(	O
Table	O
S2	O
)	O
for	O
these	O
ELISA	O
experiments	O
.	O

Based	O
on	O
the	O
commercial	O
availability	O
of	O
high	O
sensitivity	O
ELISA	O
kits	O
,	O
we	O
selected	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IFN	B-GP
-	I-GP
γ	I-GP
as	O
TH1	O
,	O
IL	B-GP
-	I-GP
4	I-GP
as	O
TH2	O
and	O
IL	B-GP
-	I-GP
17	I-GP
as	O
TH17	O
representative	O
cytokines	B-GP
.	O

We	O
found	O
the	O
sensitivity	O
of	O
the	O
TNF	B-GP
-	I-GP
α	I-GP
kit	O
to	O
be	O
too	O
low	O
for	O
TNF	B-GP
-	I-GP
α	I-GP
detection	O
in	O
the	O
tear	O
fluids	O
by	O
ELISA	O
(	O
data	O
not	O
shown	O
).	O

IFN	B-GP
-	I-GP
γ	I-GP
was	O
detectable	O
and	O
showed	O
a	O
decrease	O
in	O
keratoconus	B-DS
compared	O
to	O
pooled	O
control	O
samples	O
but	O
without	O
statistical	O
significance	O
(	O
p	O
=	O
0	O
.	O
5	O
,	O
data	O
not	O
shown	O
).	O

We	O
detected	O
14	O
.	O
2	O
±	O
8	O
.	O
6	O
pg	O
/	O
ml	O
(	O
mean	O
±	O
SD	O
)	O
of	O
IL	B-GP
-	I-GP
4	I-GP
in	O
the	O
control	O
and	O
7	O
.	O
6	O
±	O
5	O
pg	O
/	O
ml	O
in	O
the	O
KC	B-DS
pool	O
(	O
Figure	O
2	O
);	O
the	O
IL	B-GP
-	I-GP
4	I-GP
decrease	O
in	O
KC	B-DS
was	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
04	O
),	O
confirming	O
the	O
multiplex	O
immuno	O
-	O
bead	O
assay	O
results	O
(	O
Figure	O
1	O
,	O
Tables	O
2	O
and	O
3	O
).	O

IL	B-GP
-	I-GP
17	I-GP
was	O
detectable	O
in	O
one	O
control	O
and	O
3	O
keratoconus	B-DS
pools	O
in	O
one	O
experimental	O
set	O
.	O

All	O
negative	O
values	O
in	O
that	O
set	O
,	O
being	O
below	O
the	O
level	O
of	O
detection	O
,	O
were	O
set	O
at	O
the	O
minimum	O
detection	O
level	O
for	O
this	O
ELISA	O
kit	O
.	O

Based	O
on	O
these	O
limited	O
data	O
(	O
Figure	O
3	O
),	O
there	O
was	O
a	O
trend	O
towards	O
increased	O
IL	B-GP
-	I-GP
17	I-GP
(	O
72	O
.	O
5	O
±	O
59	O
.	O
2	O
pg	O
/	O
ml	O
)	O
in	O
keratoconus	B-DS
tear	O
fluids	O
compared	O
to	O
control	O
samples	O
(	O
18	O
.	O
5	O
±	O
7	O
.	O
8	O
pg	O
/	O
ml	O
).	O

Decrease	O
in	O
IL	B-GP
-	I-GP
4	I-GP
measured	O
by	O
standard	O
ELISA	O
.	O

Samples	O
shown	O
in	O
Table	O
S2	O
were	O
pooled	O
into	O
13	O
control	O
and	O
10	O
keratoconus	B-DS
samples	O
(	O
Methods	O
).	O

Each	O
ELISA	O
value	O
is	O
an	O
average	O
of	O
two	O
measurements	O
.	O

The	O
decrease	O
in	O
IL	B-GP
-	I-GP
4	I-GP
in	O
the	O
keratoconus	B-DS
pool	O
(	O
7	O
.	O
6	O
±	O
5	O
pg	O
/	O
ml	O
),	O
compared	O
to	O
controls	O
(	O
14	O
.	O
2	O
±	O
8	O
.	O
6	O
pg	O
/	O
ml	O
)	O
was	O
statistically	O
significant	O
(	O
p	O
≤	O
0	O
.	O
05	O
,	O
Mann	O
-	O
Whitney	O
test	O
).	O

The	O
horizontal	O
bar	O
indicates	O
the	O
mean	O
value	O
for	O
each	O
group	O
.	O

Increase	O
in	O
IL	B-GP
-	I-GP
17	I-GP
measured	O
by	O
standard	O
ELISA	O
.	O

Five	O
pools	O
of	O
keratoconus	B-DS
and	O
control	O
subjects	O
(	O
Table	O
S2	O
)	O
were	O
used	O
.	O

Each	O
ELISA	O
value	O
is	O
an	O
average	O
of	O
two	O
measurements	O
.	O

The	O
increase	O
in	O
IL	B-GP
-	I-GP
17	I-GP
in	O
keratoconus	B-DS
samples	O
(	O
72	O
.	O
5	O
±	O
59	O
.	O
2	O
pg	O
/	O
ml	O
)	O
compared	O
to	O
controls	O
(	O
18	O
.	O
5	O
±	O
7	O
.	O
8	O
pg	O
/	O
ml	O
),	O
was	O
statistically	O
significant	O
(	O
p	O
≤	O
0	O
.	O
05	O
,	O
Mann	O
-	O
Whitney	O
test	O
).	O

The	O
horizontal	O
bar	O
indicates	O
the	O
mean	O
value	O
for	O
each	O
group	O
.	O

Discussion	O

In	O
this	O
study	O
,	O
we	O
investigated	O
cytokines	B-GP
in	O
the	O
sera	O
and	O
tear	O
fluids	O
of	O
keratoconus	B-DS
and	O
control	O
individuals	O
to	O
determine	O
if	O
altered	O
inflammatory	O
response	O
is	O
a	O
factor	O
contributing	O
to	O
the	O
etiology	O
of	O
keratoconus	B-DS
.	O

Of	O
the	O
cytokines	B-GP
measured	O
in	O
the	O
serum	O
,	O
most	O
were	O
at	O
very	O
low	O
levels	O
and	O
none	O
showed	O
significant	O
differences	O
between	O
patients	O
and	O
control	O
individuals	O
.	O

This	O
is	O
consistent	O
with	O
the	O
idea	O
that	O
keratoconus	B-DS
is	O
not	O
associated	O
with	O
major	O
systemic	O
inflammation	O
.	O

However	O
,	O
our	O
results	O
indicate	O
perturbations	O
in	O
immune	O
related	O
homeostasis	O
in	O
the	O
tear	O
film	O
and	O
the	O
corneal	O
microenvironment	O
of	O
keratoconus	B-DS
patients	O
.	O

The	O
published	O
data	O
on	O
actual	O
baseline	O
cytokine	B-GP
concentrations	O
in	O
tear	O
fluids	O
is	O
limited	O
,	O
and	O
quite	O
variable	O
.	O

To	O
compare	O
our	O
findings	O
to	O
those	O
of	O
others	O
,	O
we	O
examined	O
the	O
literature	O
and	O
found	O
only	O
a	O
few	O
instances	O
where	O
tear	O
fluids	O
were	O
assessed	O
for	O
multiple	O
cytokines	B-GP
.	O

Since	O
only	O
a	O
limited	O
amount	O
of	O
tear	O
fluid	O
is	O
obtainable	O
without	O
stimulation	O
,	O
measuring	O
multiple	O
cytokines	B-GP
is	O
challenging	O
.	O

Li	O
and	O
coworkers	O
used	O
a	O
solid	O
phase	O
antibody	O
protein	O
array	O
-	O
based	O
method	O
to	O
estimate	O
the	O
relative	O
amounts	O
of	O
tear	O
fluid	O
cytokines	B-GP
in	O
Sjögren	B-DS
'	I-DS
s	I-DS
syndrome	I-DS
,	O
without	O
reporting	O
actual	O
levels	O
of	O
cytokines	B-GP
[	O
11	O
].	O

A	O
recent	O
study	O
used	O
an	O
immuno	O
-	O
bead	O
based	O
multiplex	O
system	O
to	O
obtain	O
baseline	O
levels	O
of	O
30	O
different	O
cytokines	B-GP
and	O
chemokines	B-GP
[	O
12	O
].	O

Others	O
have	O
examined	O
isolated	O
cytokines	B-GP
by	O
conventional	O
sandwich	O
ELISA	O
and	O
reported	O
concentrations	O
of	O
IL	B-GP
-	I-GP
6	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IL	B-GP
-	I-GP
10	I-GP
in	O
control	O
and	O
keratoconus	B-DS
subjects	O
[	O
8	O
],	O
[	O
13	O
].	O

Our	O
immuno	O
-	O
bead	O
based	O
assay	O
,	O
on	O
average	O
showed	O
high	O
levels	O
of	O
IL	B-GP
-	I-GP
4	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
CCL5	B-GP
in	O
the	O
tear	O
samples	O
of	O
control	O
subjects	O
.	O

Our	O
baseline	O
findings	O
for	O
IL	B-GP
-	I-GP
6	I-GP
and	O
TNF	B-GP
-	I-GP
α	I-GP
by	O
multiplex	O
assays	O
were	O
5	O
-	O
10	O
times	O
higher	O
than	O
the	O
reported	O
single	O
ELISA	O
measurements	O
.	O

However	O
,	O
our	O
assay	O
yielded	O
baseline	O
ranges	O
for	O
IL	B-GP
-	I-GP
10	I-GP
,	O
IL	B-GP
-	I-GP
13	I-GP
,	O
CCL5	B-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
that	O
were	O
within	O
the	O
range	O
reported	O
by	O
the	O
recent	O
immuno	O
-	O
bead	O
based	O
study	O
[	O
12	O
].	O

On	O
the	O
other	O
hand	O
,	O
our	O
estimates	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
and	O
IFN	B-GP
-	I-GP
γ	I-GP
were	O
higher	O
,	O
and	O
that	O
of	O
IL	B-GP
-	I-GP
1β	I-GP
was	O
lower	O
than	O
that	O
reported	O
in	O
the	O
earlier	O
study	O
[	O
12	O
].	O

Since	O
our	O
immuno	O
-	O
bead	O
assay	O
kit	O
is	O
different	O
from	O
that	O
used	O
in	O
the	O
other	O
study	O
,	O
some	O
of	O
this	O
difference	O
may	O
arise	O
from	O
different	O
primary	O
and	O
secondary	O
antibodies	O
.	O

In	O
addition	O
to	O
the	O
variation	O
seen	O
between	O
different	O
studies	O
,	O
the	O
range	O
for	O
each	O
cytokine	B-GP
within	O
a	O
given	O
study	O
,	O
including	O
ours	O
,	O
is	O
very	O
large	O
.	O

Some	O
of	O
this	O
variability	O
could	O
be	O
due	O
to	O
individual	O
-	O
to	O
-	O
individual	O
variation	O
in	O
cytokine	B-GP
levels	O
and	O
the	O
extent	O
of	O
tearing	O
even	O
though	O
samples	O
are	O
collected	O
without	O
direct	O
stimulation	O
.	O

Comparing	O
tear	O
fluid	O
cytokines	B-GP
in	O
the	O
control	O
and	O
keratoconus	B-DS
subjects	O
,	O
we	O
noted	O
an	O
increase	O
in	O
IL	B-GP
-	I-GP
6	I-GP
in	O
keratoconus	B-DS
,	O
in	O
agreement	O
with	O
earlier	O
reports	O
[	O
8	O
],	O
[	O
13	O
].	O

In	O
addition	O
,	O
we	O
identified	O
significant	O
decreases	O
in	O
IL	B-GP
-	I-GP
12	I-GP
and	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

The	O
latter	O
observation	O
disagrees	O
with	O
an	O
earlier	O
report	O
of	O
a	O
small	O
increase	O
in	O
TNF	B-GP
-	I-GP
α	I-GP
of	O
keratoconus	B-DS
tear	O
fluids	O
.	O

The	O
possible	O
reasons	O
for	O
this	O
difference	O
are	O
,	O
1	O
)	O
use	O
of	O
different	O
antibody	O
-	O
based	O
assays	O
,	O
2	O
)	O
actual	O
TNF	B-GP
-	I-GP
α	I-GP
levels	O
detected	O
in	O
the	O
other	O
study	O
is	O
very	O
close	O
to	O
the	O
lower	O
limit	O
of	O
TNF	B-GP
-	I-GP
α	I-GP
detection	O
by	O
the	O
conventional	O
ELISA	O
kit	O
used	O
in	O
that	O
study	O
,	O
and	O
3	O
)	O
differences	O
in	O
patient	O
population	O
between	O
the	O
two	O
studies	O
.	O

IL	B-GP
-	I-GP
12	I-GP
promotes	O
the	O
differentiation	O
of	O
TH1	O
cells	O
;	O
its	O
decrease	O
in	O
keratoconus	B-DS
is	O
consistent	O
with	O
decreases	O
in	O
two	O
signature	O
TH1	O
cytokines	B-GP
,	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
TNF	B-GP
-	I-GP
α	I-GP
.	O

In	O
severe	O
keratoconus	B-DS
,	O
IL	B-GP
-	I-GP
12	I-GP
and	O
TNF	B-GP
-	I-GP
α	I-GP
decreases	O
were	O
more	O
pronounced	O
and	O
this	O
may	O
play	O
a	O
role	O
in	O
increased	O
IL	B-GP
-	I-GP
17	I-GP
and	O
associated	O
tissue	O
degenerative	O
processes	O
.	O

Both	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
13	I-GP
cytokines	B-GP
were	O
also	O
reduced	O
in	O
keratoconus	B-DS
,	O
and	O
the	O
decrease	O
in	O
IL	B-GP
-	I-GP
4	I-GP
,	O
as	O
measured	O
by	O
conventional	O
ELISA	O
,	O
was	O
statistically	O
significant	O
.	O

IL	B-GP
-	I-GP
4	I-GP
is	O
a	O
key	O
TH2	O
cell	O
differentiation	O
cytokine	B-GP
,	O
and	O
both	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
13	I-GP
play	O
crucial	O
roles	O
in	O
amplification	O
of	O
the	O
TH2	O
response	O
through	O
up	O
regulation	O
of	O
STAT5	B-GP
,	O
STAT6	B-GP
and	O
GATA3	B-GP
transcription	O
[	O
14	O
].	O

Thus	O
,	O
decreases	O
in	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
13	I-GP
suggest	O
that	O
TH2	O
responses	O
may	O
be	O
dampened	O
in	O
keratoconus	B-DS
.	O

IL	B-GP
-	I-GP
4	I-GP
is	O
associated	O
with	O
allergic	B-DS
response	I-DS
and	O
promotes	O
the	O
synthesis	O
of	O
IgE	B-GP
[	O
15	O
].	O

Based	O
on	O
the	O
reported	O
link	O
between	O
atopy	O
and	O
keratoconus	B-DS
,	O
it	O
is	O
conceivable	O
that	O
IL	B-GP
-	I-GP
4	I-GP
levels	O
would	O
be	O
higher	O
in	O
the	O
keratoconus	B-DS
group	O
.	O

However	O
,	O
the	O
number	O
of	O
patients	O
with	O
a	O
history	O
of	O
atopy	O
in	O
our	O
samples	O
was	O
extremely	O
low	O
.	O

Thus	O
,	O
separate	O
from	O
atopy	O
,	O
the	O
decrease	O
in	O
IL	B-GP
-	I-GP
4	I-GP
we	O
see	O
may	O
be	O
pertinent	O
to	O
the	O
pathophysiology	O
of	O
keratoconus	B-DS
itself	O
.	O

How	O
do	O
our	O
tear	O
fluid	O
cytokine	B-GP
observations	O
in	O
keratoconus	B-DS
compare	O
to	O
other	O
ocular	B-DS
surface	I-DS
diseases	I-DS
?	O

A	O
study	O
reported	O
increases	O
in	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
IL	B-GP
-	I-GP
2	I-GP
,	O
IL	B-GP
-	I-GP
5	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
IL	B-GP
-	I-GP
13	I-GP
,	O
in	O
seasonal	O
allergic	B-DS
conjunctivitis	I-DS
(	O
SAC	B-DS
),	O
vernal	B-DS
keratoconjunctivitis	I-DS
(	O
VKC	B-DS
)	O
and	O
atopic	B-DS
keratoconjunctivitis	I-DS
(	O
AKC	B-DS
),	O
while	O
IL	B-GP
-	I-GP
4	I-GP
,	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
IL	B-GP
-	I-GP
10	I-GP
levels	O
were	O
increased	O
in	O
SAC	B-DS
and	O
VKC	B-DS
compared	O
to	O
controls	O
[	O
16	O
].	O

These	O
observations	O
are	O
certainly	O
different	O
from	O
the	O
cytokine	B-GP
profile	O
we	O
see	O
in	O
keratoconus	B-DS
.	O

Thus	O
,	O
the	O
broad	O
decrease	O
in	O
inflammatory	O
cytokines	B-GP
reported	O
in	O
our	O
study	O
may	O
indeed	O
be	O
keratoconus	B-DS
disease	O
-	O
specific	O
.	O

Decreased	O
IL	B-GP
-	I-GP
4	I-GP
in	O
keratoconus	B-DS
may	O
have	O
broad	O
immune	O
and	O
non	O
-	O
immune	O
consequences	O
[	O
17	O
]	O
that	O
should	O
be	O
considered	O
in	O
the	O
context	O
of	O
corneal	O
thinning	O
and	O
abnormal	O
stromal	O
extracellular	O
matrix	O
(	O
ECM	O
).	O

IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
4	I-GP
receptor	I-GP
engagement	O
through	O
the	O
JAK	B-GP
-	O
STAT	B-GP
and	O
the	O
IRS1	B-GP
/	O
2	O
pathways	O
regulate	O
cell	O
proliferation	O
and	O
tissue	O
homeostasis	O
[	O
17	O
].	O

Dermal	O
fibroblasts	O
stimulated	O
with	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
13	I-GP
up	O
regulate	O
production	O
of	O
collagens	B-GP
type	I-GP
I	I-GP
and	O
III	O
[	O
18	O
].	O

IL	B-GP
-	I-GP
4	I-GP
mediated	O
induction	O
of	O
STAT	B-GP
-	I-GP
6	I-GP
pathway	O
in	O
intrahepatic	O
cells	O
has	O
been	O
shown	O
to	O
induce	O
collagen	B-GP
synthesis	O
[	O
19	O
].	O

While	O
its	O
implication	O
in	O
hepatic	B-DS
disease	I-DS
is	O
over	O
-	O
induction	O
of	O
STAT	B-GP
-	I-GP
6	I-GP
,	O
increased	O
collagen	B-GP
,	O
and	O
fibrosis	O
,	O
reduction	O
of	O
normal	O
levels	O
of	O
IL	B-GP
-	I-GP
4	I-GP
in	O
the	O
corneal	O
environment	O
may	O
tip	O
the	O
balance	O
toward	O
poor	O
stromal	O
keratocyte	O
cell	O
survival	O
,	O
oxidative	O
stress	O
,	O
altered	O
collagen	B-GP
and	O
ECM	O
stability	O
associated	O
with	O
keratoconus	B-DS
[	O
20	O
],	O
[	O
21	O
],	O
[	O
22	O
],	O
[	O
23	O
].	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
indicate	O
reciprocal	O
interactions	O
between	O
IFN	B-GP
-	I-GP
γ	I-GP
and	O
IL	B-GP
-	I-GP
17	I-GP
,	O
and	O
between	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
17	I-GP
,	O
and	O
that	O
these	O
cytokines	B-GP
restrict	O
undue	O
amplification	O
of	O
the	O
TH17	O
response	O
[	O
24	O
].	O

It	O
is	O
possible	O
that	O
in	O
the	O
pathogenesis	O
of	O
keratoconus	B-DS
,	O
decrease	O
and	O
dysregulation	O
of	O
several	O
cytokines	B-GP
and	O
growth	B-GP
factors	I-GP
encourage	O
aggravated	O
TH17	O
response	O
,	O
production	O
of	O
metalloproteinases	B-GP
and	O
tissue	O
damage	O
.	O

Furthermore	O
,	O
TGF	B-GP
-	I-GP
β	I-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
regulate	O
differentiation	O
of	O
Treg	O
and	O
TH17	O
subsets	O
of	O
T	O
cell	O
[	O
25	O
].	O

TGF	B-GP
-	I-GP
β	I-GP
members	O
are	O
present	O
in	O
all	O
ocular	O
tissues	O
[	O
26	O
],	O
[	O
27	O
],	O
[	O
28	O
],	O
and	O
,	O
by	O
immunohistochemistry	O
we	O
detected	O
stronger	O
immunostaining	O
for	O
total	O
TGF	B-GP
-	I-GP
β	I-GP
in	O
the	O
epithelial	O
layer	O
(	O
our	O
unpublished	O
observations	O
)	O
of	O
keratoconus	B-DS
corneas	O
.	O

Moreover	O
,	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
were	O
increased	O
in	O
the	O
tear	O
fluid	O
of	O
keratoconus	B-DS
patients	O
as	O
indicated	O
in	O
this	O
study	O
and	O
reported	O
earlier	O
[	O
8	O
].	O

Indeed	O
,	O
whether	O
relative	O
TGF	B-GP
-	I-GP
β	I-GP
and	O
IL	B-GP
-	I-GP
6	I-GP
levels	O
are	O
altered	O
sufficiently	O
in	O
keratoconus	B-DS
ocular	O
tissues	O
are	O
not	O
known	O
at	O
this	O
time	O
.	O

On	O
testing	O
IL	B-GP
-	I-GP
17	I-GP
by	O
the	O
multiplex	O
immuno	O
-	O
bead	O
assay	O
,	O
we	O
could	O
not	O
detect	O
it	O
in	O
the	O
tear	O
fluid	O
.	O

However	O
,	O
using	O
an	O
IL	B-GP
-	I-GP
17	I-GP
ELISA	O
kit	O
,	O
we	O
detected	O
higher	O
levels	O
of	O
IL	B-GP
-	I-GP
17	I-GP
in	O
3	O
of	O
the	O
five	O
patient	O
pools	O
in	O
one	O
set	O
of	O
samples	O
.	O

An	O
increasing	O
number	O
of	O
studies	O
link	O
IL	B-GP
-	I-GP
17	I-GP
to	O
autoimmune	O
and	O
inflammatory	B-DS
diseases	I-DS
such	O
as	O
rheumatoid	B-DS
arthritis	I-DS
,	O
lupus	B-DS
,	O
asthma	B-DS
and	O
psoriasis	B-DS
[	O
29	O
].	O

IL	B-GP
-	I-GP
17	I-GP
is	O
produced	O
primarily	O
by	O
TH17	O
subset	O
T	O
lymphocytes	O
,	O
while	O
IL	B-GP
-	I-GP
17	I-GP
receptors	I-GP
are	O
found	O
in	O
a	O
broad	O
array	O
of	O
cell	O
types	O
including	O
fibroblasts	O
and	O
myofibroblasts	O
[	O
30	O
],	O
[	O
31	O
],	O
[	O
32	O
].	O

Multiple	O
studies	O
are	O
beginning	O
to	O
link	O
IL	B-GP
-	I-GP
17	I-GP
mediated	O
induction	O
of	O
fibroblasts	O
and	O
myofibroblasts	O
and	O
the	O
production	O
of	O
tissue	O
degrading	O
proteases	B-GP
and	O
cytokines	B-GP
[	O
31	O
],	O
[	O
33	O
],	O
[	O
34	O
],	O
[	O
35	O
].	O

Recent	O
studies	O
have	O
also	O
linked	O
IL	B-GP
-	I-GP
17A	I-GP
to	O
ocular	O
pathogenesis	O
of	O
Sjögren	B-DS
'	I-DS
s	I-DS
Syndrome	I-DS
[	O
36	O
].	O

Desiccating	O
stress	O
in	O
dry	B-DS
eye	I-DS
disease	I-DS
appears	O
to	O
also	O
involve	O
increased	O
MMP	B-GP
-	I-GP
9	I-GP
and	O
TH17	O
inflammation	O
[	O
37	O
],	O
[	O
38	O
],	O
[	O
39	O
].	O

In	O
dry	B-DS
eye	I-DS
,	O
IL	B-GP
-	I-GP
17	I-GP
promoting	O
cytokines	B-GP
have	O
been	O
shown	O
to	O
be	O
produced	O
by	O
isolated	O
T	O
cells	O
in	O
the	O
conjunctiva	O
and	O
the	O
cornea	O
[	O
37	O
].	O

In	O
our	O
hands	O
quantitative	O
reverse	B-GP
transcriptase	I-GP
polymerase	O
chain	O
reaction	O
on	O
total	O
RNA	O
from	O
scraped	O
corneal	O
epithelium	O
failed	O
to	O
detect	O
IL	B-GP
-	I-GP
17A	I-GP
.	O

Additional	O
immunohistology	O
of	O
conjunctiva	O
impressions	O
will	O
be	O
needed	O
to	O
further	O
address	O
the	O
source	O
of	O
IL	B-GP
-	I-GP
17	I-GP
producing	O
cells	O
and	O
the	O
validity	O
of	O
an	O
IL	B-GP
-	I-GP
17	I-GP
mediated	O
inflammation	O
and	O
tissue	O
damage	O
in	O
keratoconus	B-DS
.	O

Two	O
recent	O
studies	O
performed	O
proteomic	O
analyses	O
on	O
the	O
tear	O
fluids	O
of	O
unaffected	O
individuals	O
and	O
keratoconus	B-DS
patients	O
.	O

In	O
one	O
the	O
authors	O
reported	O
down	O
regulations	O
in	O
lactoferrin	B-GP
and	O
immunoglobulin	B-GP
kappa	O
chains	O
[	O
40	O
].	O

Using	O
a	O
cytokine	B-GP
antibody	O
array	O
,	O
the	O
second	O
study	O
[	O
41	O
]	O
found	O
a	O
decrease	O
in	O
TNF	B-GP
-	I-GP
α	I-GP
in	O
agreement	O
with	O
our	O
findings	O
here	O
.	O

This	O
study	O
reported	O
a	O
slight	O
increase	O
in	O
TGF	B-GP
-	I-GP
β2	I-GP
and	O
β3	O
,	O
which	O
would	O
conform	O
to	O
our	O
speculation	O
that	O
conditions	O
in	O
keratoconus	B-DS
may	O
favor	O
aggravated	O
Th17	O
response	O
.	O

In	O
summary	O
,	O
keratoconus	B-DS
is	O
a	O
complex	O
heterogeneous	O
disease	O
in	O
which	O
its	O
altered	O
corneal	O
structure	O
and	O
functions	O
may	O
be	O
related	O
to	O
multiple	O
factors	O
.	O

Our	O
data	O
suggest	O
that	O
instead	O
of	O
a	O
simple	O
increase	O
in	O
pro	O
-	O
inflammatory	O
cytokines	B-GP
,	O
there	O
may	O
be	O
a	O
complex	O
imbalance	O
between	O
pro	O
-	O
inflammatory	O
and	O
anti	O
-	O
inflammatory	O
cytokines	B-GP
,	O
and	O
possibly	O
aggravated	O
TH17	O
response	O
leading	O
to	O
altered	O
epithelial	O
and	O
stromal	O
functions	O
.	O

Clearly	O
,	O
it	O
is	O
important	O
to	O
confirm	O
the	O
observed	O
cytokine	B-GP
changes	O
in	O
a	O
larger	O
patient	O
population	O
.	O

To	O
gain	O
insights	O
into	O
the	O
immunological	O
processes	O
that	O
may	O
contribute	O
to	O
these	O
cytokine	B-GP
changes	O
it	O
is	O
important	O
to	O
track	O
down	O
the	O
cellular	O
sources	O
of	O
these	O
changes	O
.	O

While	O
historically	O
many	O
studies	O
have	O
focused	O
on	O
the	O
cornea	O
itself	O
,	O
the	O
tear	O
fluid	O
changes	O
implicate	O
the	O
conjunctiva	O
and	O
the	O
lacrimal	O
gland	O
as	O
having	O
some	O
paracrine	O
effects	O
in	O
this	O
disease	O
.	O

Materials	O
and	O
Methods	O

Samples	O

All	O
patients	O
and	O
normal	O
subjects	O
provided	O
written	O
informed	O
consent	O
according	O
to	O
a	O
protocol	O
used	O
in	O
the	O
current	O
study	O
that	O
was	O
approved	O
by	O
the	O
Johns	O
Hopkins	O
Institutional	O
Review	O
Board	O
.	O

Inclusion	O
criterion	O
for	O
participation	O
in	O
the	O
study	O
was	O
presence	O
of	O
keratoconus	B-DS
as	O
determined	O
by	O
clinical	O
examination	O
and	O
corneal	O
modeling	O
(	O
Pentacam	O
,	O
Oculus	O
,	O
Lynnwood	O
,	O
WA	O
).	O

Participants	O
completed	O
a	O
comprehensive	O
questionnaire	O
designed	O
to	O
collect	O
information	O
on	O
quality	O
of	O
life	O
,	O
contact	O
lens	O
use	O
,	O
past	O
medical	O
history	O
,	O
and	O
family	O
history	O
.	O

For	O
the	O
multiplex	O
cytokine	B-GP
analysis	O
(	O
Table	O
1	O
)	O
we	O
used	O
18	O
patients	O
(	O
61	O
%	O
males	O
,	O
mean	O
age	O
±	O
standard	O
deviation	O
(	O
SD	O
)	O
=	O
43	O
±	O
13	O
years	O
)	O
and	O
11	O
control	O
(	O
45	O
%	O
males	O
,	O
mean	O
age	O
±	O
SD	O
=	O
33	O
±	O
10	O
years	O
)	O
tear	O
samples	O
.	O

Whole	O
blood	O
was	O
collected	O
for	O
serum	O
extraction	O
.	O

Conventional	O
ELISA	O
(	O
Table	O
S2	O
)	O
was	O
performed	O
for	O
selected	O
cytokines	B-GP
on	O
pooled	O
samples	O
from	O
an	O
additional	O
29	O
keratoconus	B-DS
patients	O
(	O
76	O
%	O
male	O
,	O
mean	O
age	O
=	O
38	O
±	O
10	O
)	O
and	O
38	O
control	O
individuals	O
(	O
52	O
%	O
male	O
,	O
mean	O
age	O
=	O
40	O
±	O
12	O
).	O

These	O
samples	O
were	O
pooled	O
to	O
generate	O
13	O
control	O
and	O
10	O
keratoconus	B-DS
pools	O
.	O

The	O
keratoconus	B-DS
samples	O
were	O
pooled	O
based	O
on	O
disease	O
status	O
(	O
mild	O
,	O
moderate	O
and	O
severe	O
).	O

Severity	O
of	O
keratoconus	B-DS
was	O
graded	O
by	O
the	O
steepest	O
keratometry	O
(	O
K	O
)	O
measurement	O
with	O
<	O
45	O
diopters	O
(	O
D	O
)	O
being	O
mild	O
,	O
45	O
≤	O
K	O
≤	O
52D	O
being	O
moderate	O
,	O
and	O
severe	O
>	O
52D	O
or	O
not	O
measurable	O
.	O

Ophthalmic	O
exams	O
consisted	O
of	O
best	O
corrected	O
visual	O
acuity	O
measurements	O
,	O
slit	O
lamp	O
biomicroscopy	O
,	O
and	O
corneal	O
topography	O
using	O
the	O
Pentacam	O
.	O

Tear	O
Analysis	O

An	O
aliquot	O
of	O
5	O
to	O
8	O
µl	O
of	O
tear	O
fluid	O
was	O
collected	O
from	O
each	O
eye	O
of	O
participants	O
,	O
provided	O
that	O
the	O
eye	O
had	O
not	O
undergone	O
previous	O
surgery	O
.	O

Tear	O
samples	O
were	O
obtained	O
by	O
capillary	O
flow	O
using	O
micropipettes	O
with	O
care	O
taken	O
to	O
minimize	O
reactive	O
tear	O
production	O
.	O

Samples	O
were	O
frozen	O
to	O
−	O
80	O
°	O
C	O
within	O
one	O
hour	O
of	O
collection	O
.	O

Tear	O
samples	O
were	O
diluted	O
1	O
∶	O
25	O
in	O
phosphate	O
buffered	O
saline	O
(	O
Quality	O
Biological	O
,	O
Gaithersburg	O
,	O
MD	O
)	O
containing	O
1	O
mg	O
/	O
ml	O
BSA	B-GP
to	O
a	O
final	O
volume	O
of	O
100	O
µl	O
according	O
to	O
protocols	O
supplied	O
by	O
the	O
multiplex	O
immuno	O
-	O
bead	O
assay	O
kit	O
(	O
Human	B-OG
Bio	O
-	O
Plex	O
suspension	O
array	O
system	O
,	O
Biorad	O
).	O

The	O
concentrations	O
of	O
cytokines	B-GP
(	O
interleukin	B-GP
(	O
IL	O
)-	O
1β	O
,	O
IL	B-GP
-	I-GP
4	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
IL	B-GP
-	I-GP
13	I-GP
,	O
interferon	B-GP
(	O
IFN	O
)-	O
γ	O
,	O
tumor	B-GP
necrosis	I-GP
factor	I-GP
(	O
TNF	O
)-	O
α	O
,	O
and	O
IL	B-GP
-	I-GP
17	I-GP
)	O
and	O
the	O
chemokine	B-GP
(	I-GP
CC	I-GP
-	I-GP
motif	I-GP
)	I-GP
ligand	I-GP
5	I-GP
(	O
CCL5	B-GP
)	O
were	O
measured	O
using	O
a	O
Bio	O
-	O
Plex	O
Luminex	O
100	O
(	O
Biorad	O
).	O

Conventional	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
used	O
to	O
detect	O
levels	O
of	O
selected	O
cytokines	B-GP
in	O
pooled	O
tear	O
fluid	O
samples	O
diluted	O
1	O
∶	O
2	O
.	O

The	O
following	O
ELISA	O
kits	O
were	O
used	O
for	O
IFN	B-GP
-	I-GP
γ	I-GP
(	O
Cat	O
#	O
DIF50	O
,	O
Human	B-OG
IFN	B-GP
-	I-GP
gamma	I-GP
Quantikine	O
ELISA	O
Kit	O
,	O
R	O
&	O
D	O
Systems	O
),	O
IL	B-GP
-	I-GP
4	I-GP
(	O
Cat	O
#	O
HS400	O
,	O
Human	B-OG
IL	B-GP
-	I-GP
4	I-GP
Quantikine	O
HS	O
ELISA	O
Kit	O
,	O
R	O
&	O
D	O
Systems	O
)	O
and	O
IL	B-GP
-	I-GP
17A	I-GP
(	O
Cat	O
#	O
D1700	O
,	O
human	B-OG
IL	B-GP
-	I-GP
17	I-GP
Quantikine	O
ELISA	O
Kit	O
,	O
R	O
&	O
D	O
Systems	O
).	O

Based	O
on	O
the	O
standard	O
curves	O
the	O
detection	O
sensitivity	O
for	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
IL	B-GP
-	I-GP
4	I-GP
and	O
IL	B-GP
-	I-GP
17	I-GP
were	O
8	O
pg	O
/	O
ml	O
,	O
0	O
.	O
11	O
and	O
15	O
pg	O
/	O
ml	O
,	O
respectively	O
.	O

Serum	O
Analysis	O

An	O
aliquot	O
of	O
10	O
ml	O
blood	O
was	O
collected	O
in	O
a	O
clot	O
activating	O
tube	O
(	O
Becton	O
Dickinson	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
)	O
and	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
one	O
to	O
two	O
hours	O
before	O
spinning	O
15	O
minutes	O
at	O
4	O
°	O
C	O
.	O

Serum	O
aliquots	O
were	O
immediately	O
transferred	O
to	O
−	O
80	O
°	O
C	O
for	O
storage	O
.	O

Undiluted	O
serum	O
samples	O
were	O
assayed	O
using	O
the	O
Bio	O
-	O
Plex	O
Human	B-OG
Cytokine	B-GP
Assay	O
kit	O
,	O
(	O
Biorad	O
,	O
Hercules	O
,	O
CA	O
)	O
for	O
IL	B-GP
-	I-GP
1β	I-GP
,	O
IL	B-GP
-	I-GP
4	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
10	I-GP
,	O
IL	B-GP
-	I-GP
12	I-GP
,	O
IL	B-GP
-	I-GP
13	I-GP
,	O
IL	B-GP
-	I-GP
17	I-GP
,	O
IFN	B-GP
-	I-GP
γ	I-GP
,	O
CCL5	B-GP
,	O
TNF	B-GP
-	I-GP
α	I-GP
as	O
described	O
for	O
tear	O
fluid	O
samples	O
.	O

Statistical	O
Analysis	O

Chi	O
-	O
square	O
tests	O
were	O
used	O
to	O
determine	O
statistical	O
significance	O
for	O
categorical	O
variables	O
between	O
groups	O
.	O

Cytokine	B-GP
levels	O
in	O
keratoconus	B-DS
and	O
control	O
subjects	O
were	O
first	O
compared	O
using	O
a	O
2	O
-	O
tailed	O
,	O
Mann	O
-	O
Whitney	O
nonparametric	O
test	O
(	O
Prism	O
;	O
GraphPad	O
Software	O
,	O
San	O
Diego	O
,	O
CA	O
.),	O
with	O
a	O
p	O
-	O
value	O
≤	O
0	O
.	O
05	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O

To	O
determine	O
significant	O
(	O
p	O
≤	O
0	O
.	O
05	O
)	O
associations	O
between	O
disease	O
status	O
and	O
cytokine	B-GP
changes	O
,	O
we	O
fit	O
a	O
multivariate	O
linear	O
model	O
using	O
natural	O
log	O
transformed	O
cytokine	B-GP
levels	O
,	O
with	O
age	O
in	O
years	O
,	O
and	O
contact	O
lens	O
use	O
as	O
covariates	O
.	O

These	O
multivariate	O
analyses	O
were	O
performed	O
using	O
the	O
R	O
statistical	O
software	O
(	O
http	O
://	O
www	O
.	O
R	O
-	O
project	O
.	O
org	O
).	O

We	O
found	O
no	O
correlation	O
between	O
cytokine	B-GP
level	O
and	O
time	O
of	O
tear	O
fluid	O
collection	O
(	O
Spearmen	O
correlation	O
,	O
Prism	O
;	O
GraphPad	O
)	O
and	O
did	O
not	O
include	O
collection	O
time	O
as	O
a	O
variable	O
in	O
the	O
multivariate	O
analysis	O
.	O

Supporting	O
Information	O

Cytokine	B-GP
concentrations	O
in	O
contact	O
lens	O
users	O
and	O
non	O
-	O
users	O

(	O
DOC	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Keratoconus	B-DS
and	O
control	O
samples	O
for	O
ELISA	O
measurements	O
of	O
selected	O
cytokines	B-GP

(	O
DOC	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

